Azetukalner cut monthly focal-onset seizure frequency by a median 53.2% at 25 mg and 34.5% at 15 mg over 12 weeks versus 10.4% on placebo in the Phase 3 X-TOLE2 trial (p<0.0001 for both doses). Complete seizure freedom across the entire double-blind period was achieved by 6.5% at 25 mg versus 0.8% on placebo, with 100% responder rates rising late in treatment as steady-state was reached (last four weeks: 13.7% at 25 mg vs 4.0% placebo). Safety was consistent with prior studies; the most common adverse events were dizziness (20.5% vs 3.2% placebo), headache (8.8% vs 6.4%), somnolence (8.8% vs 7.2%), and fatigue (7.6% vs 6.4%), with low, similar rates of serious events across arms. Long-term, ≥48-month open-label extension data reported sustained seizure reduction (median percent change: -69.8% at month one, -85.1% at month 12, -90.9% at month 48) and seizure freedom for at least 12 and 24 consecutive months in 38.2% and 25.2% of participants, respectively. The core update is Xenon’s AAN presentation of pivotal X-TOLE2 results in adults with highly treatment-resistant focal epilepsy, alongside mature open-label extension outcomes and real-world evidence on titration burden. The 380-patient study enrolled a refractory cohort with a median 12.75 seizures per month, five prior anti-seizure medications, and 51.3% on three concomitant agents; roughly 40% received concomitant cenobamate and 19% had previously discontinued it. Azetukalner, a once-daily KV7 channel opener, produced rapid onset by week one and dose-dependent efficacy through the 12-week double-blind period. Xenon is targeting a U.S. NDA submission in the third quarter of 2026. Strategically, this is a bid to position azetukalner as a convenient, add-on backbone in a post-cenobamate market, where efficacy expectations are high but initiation complexity and cross-titration are persistent pain points. The no-titration profile directly attacks operational friction that has crept into ASM practice as regimens have intensified. At the same time, the program must thread a known class needle: historical concerns with earlier KV7 modulators have centered on ocular and pigmentation findings, making the absence of retinal or macular signals in the double-blind period a critical, but still provisional, differentiator that regulators will scrutinize against longer exposure. [adrotate group="1"] For sites, a no-titration, once-daily adjunct could simplify start-up visits, reduce cross-titration workload, and potentially ease enrollment of refractory patients who are already on complex polytherapy. The main operational trade-offs are familiar CNS tolerability issues—dizziness and somnolence—that can drive early discontinuation without proactive monitoring. For sponsors and CROs, the design demonstrates that robust signals are achievable in a heavily pretreated, cenobamate-exposed population, which may become the de facto standard for late-stage ASM trials. It also raises the evidentiary question for FDA: whether one pivotal plus a positive Phase 2b and extensive OLE data suffice for approval in adjunctive focal seizures, or whether a second confirmatory trial will be required, with obvious implications for timelines and capital. Looking ahead, the key watch items are regulatory stance on adequacy-of-evidence and class safety adjudication, including ocular monitoring expectations and the need for broader cardiovascular assessment with longer exposure. Clinically, durability beyond 12 months and maintenance of the emerging 100% responder signal will matter for label language and payer positioning. From a deployment standpoint, drug–drug interaction clarity in polytherapy settings, initiation in cenobamate-treated patients, and pragmatic comparisons against current add-on options will shape uptake. If FDA greenlights an NDA based on the current package, expect an advisory committee discussion focused less on efficacy and more on long-term safety guardrails and real-world implementation without titration. [adrotate group="1"] Source link: https://www.globenewswire.com/news-release/2026/04/19/3276673/33485/en/Xenon-Presents-Azetukalner-Phase-3-X-TOLE2-Study-Results-and-48-Month-Long-term-Data-in-Focal-Onset-Seizures-at-2026-AAN-Annual-Meeting.html
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
